University Medical Center Göttingen
Göttingen, Lower Saxony, 37075, Germany
NCT Number: NCT01938768
Severe external and internal bleedings are common in multiple trauma patients. Uncontrollable blood loss is the cause for about one third of all trauma deaths. A number of blood clotting mechanisms are known to be triggered by major blood losses. These mechanisms shall secure the organisms from loosing even more blood. To avoid an overshooting clotting behavior, inhibiting mechanisms occur as well. An important inhibiting (or fibrinolytic) mechanism is the fibrinolysis that is based on the conversion of plasminogen to plasmin. In severe bleeding situations this mechanism tends to overshoot and therewith contributes to the severity of the bleeding. This phenomena is called hyperfibrinolysis and is found in approximately one third of all multiple trauma patients. Mortality rates are increased in these patients. Tranexamic acid is an antifibrinolytic drug that inhibits the conversion from plasminogen to plasmin and therefore is able to limit the effects hyperfibrinolysis. A large study showed positive influence of tranexamic acid on mortality rates and blood loss in severely injured patients, when it was administered in an early clinical setting. In this study we want to answer the question wether a hyperfibrinolysis can be seen in an early prehospital (on the scene) setting and how it is influenced by an early prehospital administration of tranexamic acid.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Observational
Göttingen, Lower Saxony, 37075, Germany
In patients suffering from multiple trauma the initially responding emergency physician on the scene will take a blood sample for thrombelastometry immediately after i.v. access is established. According to the initial trauma life support protocols a number of patients will receive a dose of tranexamic acid during the initial treatment on the scene or during transport to the hospital. A second blood sample will be taken after arrival in the resuscitation area of the hospital. Thrombelastometric measurements will be performed with both blood samples and the extent of hyperfibrinolysis in both samples will be compared. In a second step the outcome of the patients who received tranexamic acid on the scene will be compared to those who did not receive the drug before reaching hospital.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Minutes after arrival on the scene
State of hyperfibrinolysis quantified by thromelastometry and PAP-Complex (Plasmin-Antiplasmin-Complex) from a blood sample taken a soon as possible on the scene
Time frame: minutes to hours after incident
State of hyperfibrinolysis quantified by thrombelastometry and PAP-Complex from a blood sample taken as soon as possible after hospital arrival
Time frame: 48 hours
units of packed RBC units transfused within 48 hours after hospital admission
Time frame: 48 hours after hospital admission
number and type of coagulation products given within 48 hours after hospital admission
Time frame: one year
length of the first ICU stay
Time frame: one year
length of stay in the acute care hospital (not rehabilitation facilities)
Time frame: 90 days
dead within 90 days after hospital admission
University of Göttingen
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03742947
Female Urogenital Diseases and Pregnancy Complications, Hemorrhage
Bordeaux, France
View Trial DetailsNCT02579941
Hyperfibrinolysis
Brussels, Belgium
View Trial DetailsNCT01887171
Early Allograft Dysfunction, Hyperfibrinolysis
Minsk, Belarus
View Trial DetailsNCT07187258
Bariatric Surgery Candidate, Haemorrhage
Giza, Manial, Egypt
View Trial Details